Xolair (Omalizumab) - Summary

XOLAIR SUMMARY

Xolair (Omalizumab) is a recombinant DNA-derived humanized IgG1(kappa) monoclonal antibody that selectively binds to human immunoglobulin E (IgE).

Xolair (Omalizumab) is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. Xolair has been shown to decrease the incidence of asthma exacerbations in these patients. Safety and efficacy have not been established in other allergic conditions.

XOLAIR NEWS HIGHLIGHTS

Media Articles Related to Xolair (Omalizumab)

Xolair® improves rate of severe asthma exacerbations
Source: Doctors Lounge - Chest Diseases

Children's Asthma Affected By Parental Expectations
Source: Health News from Medical News Today [2008.10.06]

Genes may explain racial disparities in asthma (Reuters)
Source: Y! Health Asthma News [2008.10.06]

Health Tip: Pregnancy and Asthma
Source: MedicineNet Asthma Specialty [2008.10.06]

Health Tip: Pregnancy and Asthma (HealthDay)
Source: Y! Health Asthma News [2008.10.03]

more>>

Published Studies Related to Xolair (Omalizumab)

Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma. [2008.05]

Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy. [2008.02]

Basophil histamine release decreases during omalizumab therapy in allergic asthmatics. [2008]

Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis. [2007.10]

Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects. [2007.09]

more>>

Clinical Trials Related to Xolair (Omalizumab)

Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids [Completed]

Effect of Ozone on Airway Inflammation in Allergic Asthmatics Treated With Omalizumab [Terminated]

Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy [Completed]

A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma [Completed]

Effects of Anti-IgE Antibody Omalizumab on Patients With Chronic Sinusitis [Withdrawn]

more>>